Please ensure Javascript is enabled for purposes of website accessibility

Will Good News Boost This Small-Cap Drug Company's Stock Even Higher?

By Jim Halley - May 21, 2020 at 6:21AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A do-over on one of its drugs is a potential game-changer for CymaBay.

Shares of CymaBay Therapeutics (CBAY 7.22%) have climbed nearly 143% since last week after it got great news about its orphan drug, seladelpar.

A phase 2B trial for the drug to see how it did against nonalcoholic steatohepatitis (NASH, or liver inflammation not caused by alcohol) had been sidelined by the Newark, Calif., clinical-stage biopharmaceutical company since November due to safety concerns after study pathologists found tissue damage in the livers of participants. Last week, however, the company announced that a panel of independent experts unanimously overturned earlier findings that seladelpar caused liver damage. The panel supported reinitiating clinical development of the drug, pending approval by the U.S. Food and Drug Administration (FDA).

"While we have not yet discussed full results from our investigation nor any of the panel's conclusions with the FDA, we are planning to reengage with the agency as quickly as possible," CymaBay President and CEO Sujal Shah said. 

Money and pills on a scale.

Image source: Getty Images.

That news, along with Monday's quarterly report that showed the company had trimmed its per-share losses and has $176.8 million in cash, cash equivalents, and marketable securities, was enough to cause CymaBay's stock price to jump. The question is: How speculative is buying CymaBay at this point?

First, a little cold water

CymaBay doesn't make any money yet. No one knows for sure when that will happen. It's not just that it doesn't produce positive net income -- it doesn't have any revenue at all. It's also a very small company, with 36 employees, which is good for keeping costs down, but a complication if seladelpar is approved by the FDA and the company wants to start production.

The second concern is that there's no guarantee the FDA will agree with the independent experts and allow clinical trials of seladelpar to start back up.

The third concern is that, even if trials do begin again, seladelpar's efficiency against NASH could be less than stellar, or its side effects might not be considered worth the risk.

The fourth concern is that, even given FDA approval, CymaBay might not have enough cash to complete clinical trials and to make and market the drug.

The upside, however, is huge

Estimates show that NASH affects 30 million Americans, and because the condition seems to correlate with obesity, that number is likely to grow considering our obesity epidemic.

At some point, NASH is expected to overtake hepatitis C as the leading cause of liver transplants. It's key to note that the FDA has not approved any drugs yet for the specific treatment of NASH. If seladelpar becomes the first, that will be a huge deal.

Seladelpar has other potential uses; CymaBay says it's effective against other inflammatory liver diseases. It was also being looked at for use against primary biliary cholangitis (PBC), an autoimmune liver disease that affects one in 1,000 women. That phase 2 trial was suspended after the earlier critical finding.

There are a lot of ifs, but here's the payout

If seladelpar becomes the first NASH drug approved by the FDA, it could represent a $20 billion to $35 billion market per year. That means major pharmaceuticals would be lining up -- either to buy up CymaBay or just to purchase rights to manufacture seladelpar.

The bottom line is, this isn't a stock for the faint of heart, but the reward might outweigh the risk for some pharma investors.

Jim Halley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

CymaBay Therapeutics, Inc. Stock Quote
CymaBay Therapeutics, Inc.
CBAY
$4.01 (7.22%) $0.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.